Top

Published in:

Open Access 01-12-2022 | Chronic Lymphocytic Leukemia | Review

A review on the role of mir-16-5p in the carcinogenesis

Authors: Soudeh Ghafouri-Fard, Tayyebeh Khoshbakht, Bashdar Mahmud Hussen, Sara Tharwat Abdullah, Mohammad Taheri, Mohammad Samadian

Published in: Cancer Cell International | Issue 1/2022

Abstract

miR-16-5p is microRNA with important roles in the development of diverse malignancies including neuroblastoma, osteosarcoma, hepatocellular carcinoma, cervical cancer, breast cancer, brain tumors, gastrointestinal cancers, lung cancer and bladder cancer. This miRNA has 22 nucleotides. hsa-miR-16-5p is produced by MIR16-1 gene. First evidence for its participation in the carcinogenesis has been obtained by studies reporting deletion and/or down-regulation of these miRNAs in chronic lymphocytic leukemia. Subsequent studies have shown down-regulation of miR-16-5p in a variety of cancer cell lines and clinical samples. Besides, tumor suppressor role of miR-16-5p has been verified in animal models of different types of cancers. Studies in these models have shown that over-expression of this miRNA or modulation of expression of lncRNAs that sponge this miRNA can block carcinogenic processes. In the current review, we summarize function of miR-16-5p in the development and progression of different cancers.

Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2010;1803(11):1231–43.

Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target therapy. 2016;1(1):1–9.CrossRef

Galvão-Lima LJ, Morais AH, Valentim RA, Barreto EJ. miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. Biomed Eng Online. 2021;20(1):1–20.CrossRef

Filipów S, Łaczmański Ł. Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response. Front Genet. 2019;10:169-. PubMed PMID: 30915102. eng.PubMedPubMedCentralCrossRef

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the national academy of sciences. 2002;99(24):15524-9.

Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences. 2008;105(13):5166-71.

Chava S, Reynolds CP, Pathania AS, Gorantla S, Poluektova LY, Coulter DW, et al. miR-15a‐5p, miR‐15b‐5p, and miR‐16‐5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2020;14(1):180–96.PubMedCrossRef

Zhang X, Zhang J, Liu Q, Zhao Y, Zhang W, Yang H. Circ-CUX1 accelerates the progression of neuroblastoma via miR-16-5p/DMRT2 axis. Neurochem Res. 2020;45(12):2840–55.PubMedCrossRef

Gu Z, Li Z, Xu R, Zhu X, Hu R, Xue Y, et al. miR-16-5p Suppresses Progression and Invasion of Osteosarcoma via Targeting at Smad3. Front Pharmacol. 2020;11:1324.PubMedPubMedCentralCrossRef

10.

Yu J, Zhang H, Yan L, Chang F, Jia Z, Yang X. microRNA-16-5p targeted tetraspanin 15 gene to inhibit the proliferation, migration and invasion of osteosarcoma cell through phospoinositide 3-kinase/protein kinase B signaling pathway. Zhonghua yi xue za zhi. 2020;100(21):1668–75.PubMed

11.

Liu Z, Wang Y, Wang L, Yao B, Sun L, Liu R, et al. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. J Experimental Clin Cancer Res. 2019;38(1):1–15.CrossRef

12.

Cheng B, Ding F, Huang C, Xiao H, Fei F, Li J. Role of miR-16-5p in the proliferation and metastasis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(1):137–45.PubMed

13.

Zhou Y, Huang Y, Dai T, Hua Z, Xu J, Lin Y, et al. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1. Biomed Pharmacother. 2021;133:111030.PubMedCrossRef

14.

Zhang Y, Lu C, Cui H. Long non-coding RNA SNHG22 facilitates hepatocellular carcinoma tumorigenesis and angiogenesis via DNA methylation of microRNA miR-16-5p. Bioengineered. 2021;12(1):7446–58.PubMedPubMedCentralCrossRef

15.

Zhang S, Wang W, Wu X, Liu W, Ding F. miR-16‐5p modulates the radiosensitivity of cervical cancer cells via regulating coactivator‐associated arginine methyltransferase 1. Pathol Int. 2020;70(1):12–20.PubMedCrossRef

16.

Zhao Z, Ji M, Wang Q, He N, Li Y. miR-16-5p/PDK4-mediated metabolic reprogramming is involved in chemoresistance of cervical cancer. Mol Therapy-Oncolytics. 2020;17:509–17.CrossRef

17.

Ruan L, Qian X. MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway. Biosci Rep. 2019;39(8):BSR20191611.PubMedPubMedCentralCrossRef

18.

Wang Z, Hu S, Li X, Liu Z, Han D, Wang Y, et al. MiR-16-5p suppresses breast cancer proliferation by targeting ANLN. BMC Cancer. 2021;21(1):1–12.CrossRef

19.

Qu Y, Liu H, Lv X, Liu Y, Wang X, Zhang M, et al. MicroRNA-16-5p overexpression suppresses proliferation and invasion as well as triggers apoptosis by targeting VEGFA expression in breast carcinoma. Oncotarget. 2017;8(42):72400.PubMedPubMedCentralCrossRef

20.

Zhang H, Zhang J, Dong L, Ma R. LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer. Open Med. 2021;16(1):68–80.CrossRef

21.

Krell A, Wolter M, Stojcheva N, Hertler C, Liesenberg F, Zapatka M, et al. MiR-16‐5p is frequently down‐regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy. Neuropathol Appl Neurobiol. 2019;45(5):441–58.PubMed

22.

You S, He X, Wang M, Mao L, Zhang L. Tanshinone IIA. Suppresses Glioma Cell Proliferation, Migration and Invasion Both in vitro and in vivo Partially Through miR-16-5p/Talin-1 (TLN1) Axis. Cancer Manage Res. 2020;12:11309.CrossRef

23.

Yu M, Lu W, Cao Z, Xuan T. LncRNA LINC00662 Exerts an Oncogenic Effect on Osteosarcoma by the miR-16-5p/ITPR1 Axis. Journal of oncology. 2021;2021.

24.

Xu M, Sun X, Liu Y, Chang L, Te Wang H, Wang S. hsa_circ_0005721 triggers proliferation, migration and invasion of osteosarcoma by upregulating the linear transcript TEP1. J BU ON: Official J Balkan Union Oncol. 2021;26(4):1588–94.

25.

Xie F, Xie G, Sun Q. Long noncoding RNA DLX6-AS1 promotes the progression in cervical cancer by targeting miR-16-5p/ARPP19 axis. Cancer Biother Radiopharm. 2020;35(2):129–36.PubMedCrossRef

26.

Jo H, Park Y, Kim J, Kwon H, Kim T, Lee J, et al. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells. PLoS ONE. 2020;15(10):e0240107.PubMedPubMedCentralCrossRef

27.

Zhang H, Yang K, Ren T, Huang Y, Tang X, Guo W. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3. Cell Death Dis. 2018;9(6):1–13.CrossRef

28.

Wang C, Wang Y, Wang J, Guo X. LINC00662 triggers malignant progression of chordoma by the activation of RNF144B via targeting miR-16-5p. Eur Rev Med Pharmacol Sci. 2020;24(3):1007–22.PubMed

29.

Li Z, Suo B, Long G, Gao Y, Song J, Zhang M, et al. Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer. Front Cell Dev Biology. 2020;8:1362.CrossRef

30.

Zhu C, Huang Q, Zhu H. Melatonin inhibits the proliferation of gastric cancer cells through regulating the miR-16-5p-Smad3 pathway. DNA Cell Biol. 2018;37(3):244–52.PubMedCrossRef

31.

Wang H, Di X, Bi Y, Sun S, Wang T. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p. Bioengineered. 2021;12(1):1791–802.PubMedPubMedCentralCrossRef

32.

Zhuo S, Sun M, Bai R, Lu D, Di S, Ma T, et al. Long intergenic non-coding RNA 00473 promotes proliferation and migration of gastric cancer via the miR-16-5p/CCND2 axis and by regulating AQP3. Cell Death Dis. 2021;12(5):1–14.CrossRef

33.

Wang Q, Chen Y, Lu H, Wang H, Feng H, Xu J, et al. Quercetin radiosensitizes non-small cell lung cancer cells through the regulation of miR‐16‐5p/WEE1 axis. IUBMB Life. 2020;72(5):1012–22.PubMedCrossRef

34.

Peng Q, Chen Y, Li C. Long noncoding RNA Linc00210 promotes non-small cell lung cancer progression via sponging miR-16-5p/PTK2 axis. Eur Rev Med Pharmacol Sci. 2020;24(18):9438–52.PubMed

35.

Du R, Jiang F, Yin Y, Xu J, Li X, Hu L, et al. Knockdown of lncRNA X inactive specific transcript (XIST) radiosensitizes non-small cell lung cancer (NSCLC) cells through regulation of miR-16-5p/WEE1 G2 checkpoint kinase (WEE1) axis. Int J ImmunoPathol Pharmacol. 2021;35:2058738420966087.PubMedPubMedCentralCrossRef

36.

Wu H, Wei M, Jiang X, Tan J, Xu W, Fan X, et al. lncRNA PVT1 promotes tumorigenesis of colorectal cancer by stabilizing miR-16-5p and interacting with the VEGFA/VEGFR1/AKT axis. Mol Therapy-Nucleic Acids. 2020;20:438–50.CrossRef

37.

Huang X, Hou Y, Weng X, Pang W, Hou L, Liang Y, et al. Diethyldithiocarbamate-copper complex (CuET) inhibits colorectal cancer progression via miR-16-5p and 15b-5p/ALDH1A3/PKM2 axis-mediated aerobic glycolysis pathway. Oncogenesis. 2021;10(1):1–16.CrossRef

38.

Xu Y, Shen L, Li F, Yang J, Wan X, Ouyang M. microRNA-16‐5p‐containing exosomes derived from bone marrow‐derived mesenchymal stem cells inhibit proliferation, migration, and invasion, while promoting apoptosis of colorectal cancer cells by downregulating ITGA2. J Cell Physiol. 2019;234(11):21380–94.PubMedCrossRef

39.

Papagiannopoulos CI, Theodoroula NF, Vizirianakis IS. miR-16-5p Promotes Erythroid Maturation of Erythroleukemia Cells by Regulating Ribosome Biogenesis. Pharmaceuticals. 2021;14(2):137.PubMedPubMedCentralCrossRef

40.

Wang F, Wang W, Lu L, Xie Y, Yan J, Chen Y, et al. MicroRNA–16–5p regulates cell survival, cell cycle and apoptosis by targeting AKT3 in prostate cancer cells. Oncol Rep. 2020;44(3):1282–92.PubMedCrossRef

41.

Wang F, Mao A, Tang J, Zhang Q, Yan J, Wang Y, et al. microRNA-16‐5p enhances radiosensitivity through modulating Cyclin D1/E1–pRb–E2F1 pathway in prostate cancer cells. J Cell Physiol. 2019;234(8):13182–90.PubMedCrossRef

42.

Chen S-S, Tang C-H, Chie M-J, Tsai C-H, Fong Y-C, Lu Y-C, et al. Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells. Cell Death Dis. 2019;10(1):1–12.CrossRef

43.

Sang S, Zhang Z, Qin S, Li C, Dong Y. MicroRNA-16-5p inhibits osteoclastogenesis in giant cell tumor of bone. BioMed research international. 2017;2017.

44.

Feng X, Dong X, Wu D, Zhao H, Xu C, Li H. Long noncoding RNA small nucleolar RNA host gene 12 promotes papillary thyroid carcinoma cell growth and invasion by targeting miR-16-5p. Histol Histopathol. 2019;35(2):217–24.PubMed

45.

Ren Y, Huang W, Weng G, Cui P, Liang H, Li Y. lncrna PVT1 promotes proliferation, invasion and epithelial–mesenchymal transition of renal cell carcinoma cells through downregulation of mir-16-5p. OncoTargets and therapy. 2019;12:2563.PubMedPubMedCentralCrossRef

46.

He J, Qiu Z, Zhang H, Gao Z, Jiang Y, Li Z, et al. MicroRNA–16–5p/BIMP1/NF–κB axis regulates autophagy to exert a tumor–suppressive effect on bladder cancer. Mol Med Rep. 2021;24(2):1–10.CrossRef

47.

Liu Y, Huang X, Guo L, Luo N. LINC00649 Facilitates the Cellular Process of Bladder Cancer Cells via Signaling Axis miR-16-5p/JARID2. Urologia Internationalis. 2021:1–9.

48.

Gao Y, Ouyang X, Zuo L, Xiao Y, Sun Y, Chang C, et al. R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway. Mol Therapy-Oncolytics. 2021;23:65–81.CrossRef

49.

Casabonne D, Benavente Y, Seifert J, Costas L, Armesto M, Arestin M, et al. Serum levels of hsa-miR‐16‐5p, hsa‐miR‐29a‐3p, hsa‐miR‐150‐5p, hsa‐miR‐155‐5p and hsa‐miR‐223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. Int J Cancer. 2020;147(5):1315–24.PubMedCrossRef

50.

Saral MA, Tuncer SB, Odemis DA, Erdogan OS, Erciyas SK, Saip P, et al. New biomarkers in peripheral blood of patients with ovarian cancer: high expression levels of miR-16-5p, miR-17-5p, and miR-638. Archives of Gynecology and Obstetrics. 2021:1–9.

51.

Lee TJ, Yuan X, Kerr K, Yoo JY, Kim DH, Kaur B, et al. Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury. Pharmacol Rev. 2020 Jul;72(3):639–67. PubMed PMID: 32554488. Pubmed Central PMCID: PMC7300323. Epub 2020/06/20. eng.PubMedPubMedCentralCrossRef

Title: A review on the role of mir-16-5p in the carcinogenesis
Authors: Soudeh Ghafouri-Fard
Tayyebeh Khoshbakht
Bashdar Mahmud Hussen
Sara Tharwat Abdullah
Mohammad Taheri
Mohammad Samadian
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Chronic Lymphocytic Leukemia
osteosarcoma
Neuroblastoma
Neuroblastoma
Hepatocellular Carcinoma
Osteosarcoma
Hepatocellular Carcinoma
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02754-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy

FGFR1 is a potential therapeutic target in neuroblastoma

Prostate cancer in omics era

SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways

Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian

Systematic analysis of the role of SLC52A2 in multiple human cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer